Supernus Pharmaceuticals Competitors and Similar CompaniesClear all
Supernus Pharmaceuticals's competitors and similar companies include Neuraxpharm, moksha8 Pharmaceuticals, Vanda Pharmaceuticals and Intra-Cellular Therapies.
 Supernus Pharmaceuticals Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. |  Neuraxpharm Neuraxpharm is a pharmaceutical company focusing on the treatment of central nervous system (CNS) disorders. |  moksha8 Pharmaceuticals Moksha8 is a pharmaceutical company which provides therapeutics for the treatment of central nervous system and mental health disorders. |  Vanda Pharmaceuticals Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. |  Intra-Cellular Therapies Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS. | |
Founding Date | Founding Date 2005 | Founding Date 1985 | Founding Date 2006 | Founding Date 2002 | Founding Date 2002 |
Type | Type Public | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Rockville, US HQ | Locations Langenfeld (Rheinland), DE HQ Gießhübl, AT Hradec Králové, CZ Paris, FR Budapest, HU Dublin, IE Ascoli Piceno, IT see more | Locations Berwyn, US HQ Ciudad De México, MX | Locations Washington, US HQ Berlin, DE London, GB | Locations New York, US HQ |
Employees | Employees 6527% increase | Employees 8131% increase | Employees 3783% increase | Employees 2845% increase | Employees 330352% increase |
Valuation ($) | Valuation ($) 1.9 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 273.4 m | Valuation ($) 8.1 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $661.8m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $198.8m (FY, 2024) | Revenue (est.) $680.9m (FY, 2024) |
Net income | Net income $73.9m (FY, 2024) | Net income N/A | Net income N/A | Net income ($18.9m) (FY, 2024) | Net income ($74.7m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 69.5m | Total funding raised N/A | Total funding raised $ 224.1m | Total funding raised $ 54m | Total funding raised $ 225.3m |
For sources of this data, please see the company profile
View Company Profiles
Neuraxpharm
HQ
Langenfeld (Rheinland), DE
Employees
813↑ 1% increase
Neuraxpharm is a pharmaceutical company focusing on the treatment of central nervous system (CNS) disorders.
View companymoksha8 Pharmaceuticals
HQ
Berwyn, US
Employees
378↑ 3% increase
Moksha8 is a pharmaceutical company which provides therapeutics for the treatment of central nervous system and mental health disorders.
View companyVanda Pharmaceuticals
HQ
Washington, US
Employees
284↑ 5% increase
Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.
View companyIntra-Cellular Therapies
HQ
New York, US
Employees
330
Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.
View company